Medically reviewed by Mary Choy, PharmD Biologics work by targeting proteins that cause inflammation in ulcerative colitis.

The deal is expected to close sometime in the third quarter. MORF-057 is an α4β7 integrin inhibitor currently in a pair of phase 2 trials in ulcerative colitis and a third in Crohn’s disease.

The $30-per-share offer is due to close on Friday, and will help fund pivotal trials of integrin inhibitor bexotegrast (PLN-74809) and a follow-up drug PLN-101095 that is being developed for solid ...